SAB BIOTHERAPEUTICS, INC. Interest Expense Nonoperating
SAB BIOTHERAPEUTICS, INC. (SABS) reported Interest Expense Nonoperating of $62.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $62.00K, a 3.13% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $62.74K, a 9.80% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $63.46K, a 10.46% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $43.29K, a 44.52% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. interest expense nonoperating for fiscal 2025 was $240.66K, a 24.41% decline from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. interest expense nonoperating for fiscal 2024 was $318.40K, a 0.99% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. interest expense nonoperating for fiscal 2023 was $315.28K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 3 month as first filed | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 6 month as first filed | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $62.00K 10-Q · filed 2026-08-06 | $125.00K 10-Q · filed 2026-08-06 | $188.21K derived: sum of 3 quarters · filed 2026-08-06 | $231.50K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $62.74K 10-Q · filed 2026-05-12 | $126.21K derived: sum of 2 quarters · filed 2026-05-12 | $169.50K derived: sum of 3 quarters · filed 2026-05-12 | $233.50K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | $63.46K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $106.75K derived: sum of 2 quarters · filed 2026-03-09 | $170.75K derived: sum of 3 quarters · filed 2026-08-06 | $240.66K 10-K · filed 2026-03-09 | ||
| 2025-09-30 | $43.29K 10-Q · filed 2025-11-14 | $107.29K derived: sum of 2 quarters · filed 2026-08-06 | $177.20K 10-Q · filed 2025-11-14 | $247.73K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $64.00K 10-Q · filed 2026-08-06 | $64.34K 10-Q · filed 2025-08-07 | $134.00K 10-Q · filed 2026-08-06 | $133.91K 10-Q · filed 2025-08-07 | $204.44K derived: sum of 3 quarters · filed 2026-08-06 | $282.48K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $69.56K 10-Q · filed 2026-05-12 | $140.44K derived: sum of 2 quarters · filed 2026-05-12 | $218.48K derived: sum of 3 quarters · filed 2026-05-12 | $311.60K derived: sum of 4 quarters · filed 2026-05-12 | ||
| 2024-12-31 | $70.88K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $148.91K derived: sum of 2 quarters · filed 2026-03-09 | $242.03K derived: sum of 3 quarters · filed 2026-03-09 | $318.40K 10-K · filed 2026-03-09 | ||
| 2024-09-30 | $78.04K 10-Q · filed 2025-11-14 | $171.16K derived: sum of 2 quarters · filed 2025-11-14 | $247.53K 10-Q · filed 2025-11-14 | $325.40K derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2024-06-30 | $93.12K 10-Q · filed 2025-08-07 | $169.49K 10-Q · filed 2025-08-07 | $247.37K derived: sum of 3 quarters · filed 2025-08-07 | $317.07K derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | $76.37K 10-Q · filed 2025-05-09 | $154.25K derived: sum of 2 quarters · filed 2025-05-09 | $223.95K derived: sum of 3 quarters · filed 2025-05-09 | |||
| 2023-12-31 | $77.88K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $147.58K derived: sum of 2 quarters · filed 2025-03-31 | $315.28K 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $69.70K 10-Q · filed 2024-11-06 | $237.41K 10-Q · filed 2024-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |